Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

NCT00574288 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Part 1: Daratumumab
DRUG: Part 2: Daratumumab
OTHER: Methylprednisolone
OTHER: Dexamethasone

Sponsor

Janssen Research & Development, LLC